|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
2
|
Yang J and Weinberg RA:
Epithelial-mesenchymal transition: at the crossroads of development
and tumor metastasis. Developmental Cell. 14:818–829. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Massagué J: TGFbeta in Cancer. Cell.
134:215–230. 2008.
|
|
5
|
Stefan Grünert MJHB: Diverse cellular and
molecular mechanisms contribute to epithelial plasticity and
metastasis. Nat Rev Mol Cell Biol. 4:657–665. 2003.PubMed/NCBI
|
|
6
|
Voulgari A and Pintzas A:
Epithelial-mesenchymal transition in cancer metastasis: mechanisms,
markers and strategies to overcome drug resistance in the clinic.
Biochim Biophys Acta. 1796:75–90. 2009.PubMed/NCBI
|
|
7
|
Zhao XL, Sun T, Che N, et al: Promotion of
hepatocellular carcinoma metastasis through matrix
metalloproteinase activation by epithelial-mesenchymal transition
regulator Twist1. J Cell Mol Med. 15:691–700. 2011. View Article : Google Scholar
|
|
8
|
Cho KH, Jeong KJ, Shin SC, Kang J, Park CG
and Lee HY: STAT3 mediates TGF-beta1-induced TWIST1 expression and
prostate cancer invasion. Cancer Lett. 336:167–173. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kalluri RWR: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Akhurst RJ and Derynck R: TGF-beta
signaling in cancer - a double-edged sword. Trends Cell Biol.
11:S44–S51. 2001.PubMed/NCBI
|
|
11
|
Sánchez-Tilló E, Liu Y, de Barrios O, et
al: EMT-activating transcription factors in cancer: beyond EMT and
tumor invasiveness. Cellular and molecular life sciences. Cell Mol
Life Sci. 69:3429–3456. 2012.PubMed/NCBI
|
|
12
|
Wood ZASE, Schröder E, Robin Harris J and
Poole LB: Structure, mechanism and regulation of peroxiredoxins.
Trends Biochem Sci. 28:32–40. 2003. View Article : Google Scholar
|
|
13
|
Kang DH, Lee DJ, Lee KW, et al:
Peroxiredoxin II is an essential antioxidant enzyme that prevents
the oxidative inactivation of VEGF receptor-2 in vascular
endothelial cells. Mol Cell. 44:545–558. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ishii T, Warabi E and Yanagawa T: Novel
roles of peroxiredoxins in inflammation, cancer and innate
immunity. J Clin Biochem Nutr. 50:91–105. 2012.PubMed/NCBI
|
|
15
|
Rhee SG, Chae HZ and Kim K:
Peroxiredoxins: a historical overview and speculative preview of
novel mechanisms and emerging concepts in cell signaling. Free
Radic Biol Med. 38:1543–1552. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Han YH, Kim HS, Kim JM, Kim SK, Yu DY and
Moon EY: Inhibitory role of peroxiredoxin II (Prx II) on cellular
senescence. FEBS Letters. 579:4897–4902. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee KW, Lee DJ, Lee JY, Kang DH, Kwon J
and Kang SW: Peroxiredoxin II restrains DNA damage-induced death in
cancer cells by positively regulating JNK-dependent DNA repair. J
Biol Chem. 286:8394–8404. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Choi MH, Lee IK, Kim GW, et al: Regulation
of PDGF signalling and vascular remodelling by peroxiredoxin II.
Nature. 435:347–353. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Agrawal-Singh S, Isken F, Agelopoulos K,
et al: Genome-wide analysis of histone H3 acetylation patterns in
AML identifies PRDX2 as an epigenetically silenced tumor suppressor
gene. Blood. 119:2346–2357. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tiwari N, Gheldof A, Tatari M and
Christofori G: EMT as the ultimate survival mechanism of cancer
cells. Semin Cancer Biol. 22:194–207. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Y and Shang Y: Epigenetic control of
epithelial-to-mesenchymal transition and cancer metastasis. Exp
Cell Res. 319:160–169. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ko H, So Y, Jeon H, et al:
TGF-beta1-induced epithelial-mesenchymal transition and acetylation
of Smad2 and Smad3 are negatively regulated by EGCG in human A549
lung cancer cells. Cancer Lett. 335:205–213. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jarvis RM, Hughes SM and Ledgerwood EC:
Peroxiredoxin 1 functions as a signal peroxidase to receive,
transduce, and transmit peroxide signals in mammalian cells. Free
Radic Biol Med. 53:1522–1530. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Manandhar G, Miranda-Vizuete A, Pedrajas
JR, et al: Peroxiredoxin 2 and peroxidase enzymatic activity of
mammalian spermatozoa. Biol Reprod. 80:1168–1177. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Neumann CA, Cao J and Manevich Y:
Peroxiredoxin 1 and its role in cell signaling. Cell Cycle.
8:4072–4078. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ha B, Kim EK, Kim JH, et al: Human
peroxiredoxin 1 modulates TGF-β1-induced epithelial-mesenchymal
transition through its peroxidase activity. Biochem Biophys Res
Commun. 421:33–37. 2012.PubMed/NCBI
|
|
27
|
Chen X, Halberg RB, Burch RP and Dove WF:
Intestinal adenomagenesis involves core molecular signatures of the
epithelial-mesenchymal transition. J Mol Histol. 39:283–294. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee DJ, Kang DH, Choi M, et al:
Peroxiredoxin-2 represses melanoma metastasis by increasing
E-Cadherin/beta-Catenin complexes in adherens junctions. Cancer
Res. 73:4744–4757. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lu W, Fu Z, Wang H, Feng J, Wei J and Guo
J: Peroxiredoxin 2 is upregulated in colorectal cancer and
contributes to colorectal cancer cells’ survival by protecting
cells from oxidative stress. Mol Cell Biochem. 387:261–270.
2014.PubMed/NCBI
|
|
30
|
Lu W, Fu Z, Wang H, Feng J, Wei J and Guo
J: Peroxiredoxin 2 knockdown by RNA interference inhibits the
growth of colorectal cancer cells by downregulating Wnt/β-catenin
signaling. Cancer Lett. 343:190–199. 2014.PubMed/NCBI
|
|
31
|
Johnson RM, Ho YS, Yu DY, et al: The
effects of disruption of genes for peroxiredoxin-2, glutathione
peroxidase-1, and catalase on erythrocyte oxidative metabolism.
Free Radic Biol Med. 48:519–525. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shin SY, Kim CG, Jho EH, et al: Hydrogen
peroxide negatively modulates Wnt signaling through downregulation
of beta-catenin. Cancer Lett. 212:225–231. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Onder TT, Gupta PB, Mani SA, et al: Loss
of E-cadherin promotes metastasis via multiple downstream
transcriptional pathways. Cancer Res. 68:3645–3654. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhu QC, Gao RY, Wu W and Qin HL:
Epithelial-mesenchymal transition and its role in the pathogenesis
of colorectal cancer. Asian Pac J Cancer Prev. 14:2689–2698. 2013.
View Article : Google Scholar : PubMed/NCBI
|
